Publication | Closed Access

The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B—a prerequisite for clinical development

VaccinationOncologyMedicineImmunologyTherapeutic VaccineClinical DevelopmentCancer VaccineEd-b—a PrerequisiteImmunotherapeuticsTumor TargetingAnti-cancer AgentCancer TreatmentVaccine DesignImmunotherapyPharmacologyCancer Research